A Double-blind, Multi-center, Randomized, Placebo Controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel) Administered Vaginally in the Treatment of Bacterial Vaginosis.

Trial Profile

A Double-blind, Multi-center, Randomized, Placebo Controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel) Administered Vaginally in the Treatment of Bacterial Vaginosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2012

At a glance

  • Drugs Astodrimer (Primary)
  • Indications Bacterial infections; Bacterial vaginosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Mar 2011 Planned End Date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top